Work | Therapeutic Paths
Putting kids first with results-oriented pediatric cancer research
SKC’s top priority is to create more effective and less toxic treatment options for kids with the deadliest childhood cancers. We envision a different way of working on this problem that puts kids first — before lab data, before institutional priorities, before profit and agendas.
Therapeutic benefit is the main clinical driver of all SKC therapeutic development projects. SKC does not support trials designed to demonstrate incremental improvements over previous trials or that set the efficacy bar low in order to meet endpoints. Guided by our vision, mission, and core values, SKC is always seeking new therapeutic ideas within the identified Therapeutic Paths:
- Implicated Molecular Pathways
- Tumor Cell Surface Receptors
- Tumor Initiating Cells (Cancer Stem Cells)
- Embryonic Development Mechanism
SKC strongly believes that all clinical trials or pilot studies should be designed to be therapeutically beneficial. Most Phase I trials investigate a single agent even if there is anecdotal evidence that combining this agent with other therapies would provide more therapeutic benefit.
SKC strives to support therapeutic options for children that are more effective and less toxic than standard chemotherapies and radiotherapies. In some cases, however, a new discovery that is potentially curative may also induce toxicity. When this occurs, the therapeutic option will be assessed to determine whether the potential benefits may outweigh the potential risks.